{Reference Type}: Journal Article
{Title}: Systemic therapy for endometrial stromal sarcomas: current treatment options.
{Author}: Serkies K;Pawłowska E;Jassem J;
{Journal}: Ginekol Pol
{Volume}: 87
{Issue}: 8
{Year}: 2016
{Factor}: 1.216
{DOI}: 10.5603/GP.2016.0051
{Abstract}: Uterine endometrial stromal sarcomas including true low-grade endometrial stromal sarcoma (LG-ESS) and high-grade (HG-ESS) or undifferentiated endometrial sarcoma (UES) constitute a group of rare, aggressive malignancies. Most LG-ESSs express steroid receptors. Surgery is the principal primary therapy for endometrial stromal sarcomas and should be considered in all cases. These malignancies are relatively radio- and chemoresistant. Chemotherapy is used in recurrent and advanced HG-ESS and UES. Currently, the combination of gemcitabine and docetaxel is considered the most effective regimen, but at the expense of substantial toxicity. In steroid receptor positive advanced LG-ESS hormonal therapy, mainly with progestins, allows in some patients for a long-term survival. Aromatase inhibitors seem to be equally effective as first- and subsequent-line of treatment, and are well tolerated. The role of molecular-targeted therapies in endometrial stromal sarcomas remains to be established.